A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 35, Issue 12, 2008, Pages 2344-2347

  Yeap, Swan S ^a,c   Fauzi, Ahmad R ^b   Kong, Norella C T ^b   Halim, Abdul G ^b   Soehardy, Zainudin ^b   Rahimah, Ismail ^b   Chow, Sook K ^a   Goh, Emily M L ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^c SUBANG JAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Alendronate; Calcitriol; Glucocorticoid; Osteoporosis; Premenopausal; Systemic lupus erythematosus

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; CALCIUM CARBONATE; CORTICOSTEROID;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIP; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; OSTEOPENIA; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OSTEOPOROSIS; PREMENOPAUSE; YOUNG ADULT;

EID: 57349138900     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080634     Document Type: Article

References (31)

1. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28.
2. LoCasio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51.
3. Sambrook P, Birmingham J, Kempler S, et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990;5:1211-6.
4. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis - a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
5. Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995;57:115-9.
6. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
7. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
8. Reginster JY, Kuntz D, Verdicht W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9:75-81.
9. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
10. Saag K, Emkey R, Schnitzler TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 1998;339:292-9.
11. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
12. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
13. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:176-86.
14. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-5.
15. Yeap SS, Fauzi AR, Kong NC, et al. Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids. Lupus 2008; (in press).
16. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999;42:882-90.
17. Dhillon VB, Davies MC, Hall ML, et al. Assessment of effect of oral steroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry. Ann Rheum Dis 1990;49:624-6.
18. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993;36:1726-34.
19. Pons F, Peris P, Guanabens N, et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women. Br J Rheumatol 1995;34:742-6.
20. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F, Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995;54:274-6.
21. Houssiau FA, Lefèbvre C, Depresseux G, Lambert M, Devogelaer J-P, Nagant de Deuxchaisnes C. Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996;35:244-7.
22. Sinigaglia L, Varenna M, Binelli L, et al. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women. J Rheumatol 1999;26:1280-4.
23. Li EK, Tam LS, Young RP, Ko GTC, Li M, Lau EMC. Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. Br J Rheumatol 1998;37:405-10.
24. Jardinet D, Lefèbvre C, Depresseux G, Lambert M, Devogelaer J-P, Houssiau FA. Longitudinal analysis of bone mineral density in premenopausal female SLE patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology Oxford 2000;39:389-92.
25. Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S. Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 2003;30:2365-8.
26. American College of Rheumatology Ad Hoc Committee on Glucocorticoid Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-503.
27. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005;64:176-8.
28. Welten DC, Kemper HCG, Post GB, Van Staveren WA. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. J Nutr 1995;125:2802-13.
29. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation series. Osteoporos Int 2004;15:589-602.
30. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002;17:1512-26.
31. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology Oxford 2005;44:813-8.